Spots Global Cancer Trial Database for clear cell carcinoma
Every month we try and update this database with for clear cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. | NCT04458597 | Endometrioid Ad... Serous Carcinom... Clear Cell Carc... Carcinosarcoma Dedifferentiate... | Image-guided ad... | 18 Years - | Lawson Health Research Institute | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. | NCT04458597 | Endometrioid Ad... Serous Carcinom... Clear Cell Carc... Carcinosarcoma Dedifferentiate... | Image-guided ad... | 18 Years - | Lawson Health Research Institute | |
| A Study of Nivolumab in Selected Uterine Cancer Patients | NCT03241745 | Uterine Cancer Endometrial Car... Carcinosarcoma Leiomyosarcoma Undifferentiate... High Grade Endo... Clear Cell Carc... | Nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | NCT01625351 | Ewing Sarcoma Gastrointestina... Germ Cell Tumor Hepatic Tumor Lymphoma Wilms Tumor Rhabdoid Tumor Clear Cell Carc... Renal Cell Carc... Melanoma Neuroblastoma Rhabdomyosarcom... Non-rhabdomyosa... | alemtuzumab fludarabine sirolimus Busulfan melphalan stem cells CliniMACS | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | NCT01824615 | Ovarian Cancer Adverse Effects | Sunitinib | 20 Years - 80 Years | Cathay General Hospital | |
| A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers | NCT00231829 | Uterine Cancer | Celecoxib | 18 Years - | Montefiore Medical Center | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | NCT01824615 | Ovarian Cancer Adverse Effects | Sunitinib | 20 Years - 80 Years | Cathay General Hospital | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) | NCT01732432 | Endometrioid Ca... Clear Cell Carc... Endometriosis | 30 Years - 85 Years | University Hospital, Basel, Switzerland | ||
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | NCT06023862 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Vulvar Cancer Vagina Neoplasm Clear Cell Carc... | Dostarlimab Bevacizumab Doxorubicin Gemcitabine Paclitaxel Pegylated lipos... | 18 Years - | Yonsei University | |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | NCT06023862 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Vulvar Cancer Vagina Neoplasm Clear Cell Carc... | Dostarlimab Bevacizumab Doxorubicin Gemcitabine Paclitaxel Pegylated lipos... | 18 Years - | Yonsei University | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | NCT05032040 | Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast... | vudalimab | 18 Years - | Xencor, Inc. | |
| High-dose Bevacizumab in Advanced Renal Carcinoma Patients | NCT00455975 | Renal Cancer Kidney Cancer | Bevacizumab | 18 Years - | SCRI Development Innovations, LLC | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Ovarian Clear Cell Adenocarcinoma Review | NCT02129036 | Ovarian Cysts | 30 Years - 70 Years | Cathay General Hospital | ||
| A Study of Nivolumab in Selected Uterine Cancer Patients | NCT03241745 | Uterine Cancer Endometrial Car... Carcinosarcoma Leiomyosarcoma Undifferentiate... High Grade Endo... Clear Cell Carc... | Nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy | NCT05460000 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | 3 cycles chemot... 6 cycles chemot... | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | NCT05032040 | Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast... | vudalimab | 18 Years - | Xencor, Inc. | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | NCT00563784 | Non-Small Cell ... Lung Cancer | Erlotinib Carboplatin Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers | NCT00231829 | Uterine Cancer | Celecoxib | 18 Years - | Montefiore Medical Center | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ovarian Clear Cell Adenocarcinoma Review | NCT02129036 | Ovarian Cysts | 30 Years - 70 Years | Cathay General Hospital | ||
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | NCT04623502 | Kidney Cancer Renal Cell Carc... Clear Cell Carc... Urothelial Carc... Metastatic Kidn... Metastatic Urot... Papillary Renal... Chromophobe Ren... Fumarate Hydrat... Succinate Dehyd... HLRCC Hereditary Leio... | 13C-Glucose 13C-Acetate 13C-Lactate 13C-Glutamine 13C-Fructose | 18 Years - | University of Texas Southwestern Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
